• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·4544.T
Share

H.U. Group Holdings, Inc. Stocks

¥ 3388Last Updated 10.09.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

¥ 1.24B

¥ 3388
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1950 and headquartered in Tokyo, Japan, H.U. Group Holdings, Inc. (formerly Miraca Holdings Inc. until its rebranding in July 2020) provides an extensive array of laboratory testing products and services through its subsidiaries across Japan. The company delivers diagnostic testing and associated services to medical facilities, supports self-medication initiatives, and conducts testing for food, environmental samples, and cosmetic products. Additionally, it offers testing solutions tailored for corporate health insurance programs. The group is deeply involved in the research, development, manufacturing, and commercialization of in vitro diagnostic devices. Its product lineup features the LUMIPULSE, an automated chemiluminescent enzyme immunoassay system that supplies reagents for the detection of infectious diseases, various cancers, and lifestyle-related conditions to medical institutions and diagnostic centers. H.U. Group also produces the ESPRINE series of rapid diagnostic kits for ailments such as influenza, hepatitis B, and the novel coronavirus, alongside supplying essential ingredients for test drugs. Beyond diagnostics, the company offers crucial support services for hospital administration, including assistance during surgical and endoscope procedures, inspection and maintenance of medical equipment, and in-hospital logistics and transportation management. Furthermore, it addresses the elderly care market by renting and selling specialized equipment and supplies, and by providing in-home nursing care services.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 4544.T is 3209 and suggests 6.3% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.09.2026 00:58

Data from some Revolut customers was leaked

12.09.2026 16:01

Small caps last week: Chewy's earnings miss, Signet's best day ever, AE rethinks ads

12.09.2026 13:01

The iPhone Reboot, the AGI Era, and Silicon Valley's Right Turn

12.09.2026 05:06

Spam from OpenAI's AI agents disrupted the developer service for four days

12.09.2026 03:52

Citrini, the founder who spooked the market with his prediction of AI threats, has sold the company. What's next?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026